Concourse Financial Group Securities, Inc. Unicycive Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
46.8MCall Options Held
0Put Options Held
0-
Octagon Capital Advisors LP New York, NY8.56MShares$5.91 Million0.85% of portfolio
-
Great Point Partners LLC Greenwich, CT8.56MShares$5.91 Million1.62% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$3.5 Million0.28% of portfolio
-
Walleye Capital LLC Plymouth, MN5MShares$3.45 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.47MShares$3.08 Million0.27% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $10.4M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...